title: Effect of daytime, weekday and year of admission on outcome in acute ischaemic stroke patients treated with thrombolytic therapy.
abstract: BACKGROUND
  Since doubts were raised, if a challenging medical procedure such as acute stroke treatment including thrombolysis with recombinant tissue plasminogen activator (rTPA) is available with identical standard and outcome 24 h and 7 days a week our aim was to examine if acute stroke patients defined by onset-admission time (OAT) of <or= 3 h were treated differently or had distinct outcome when admitted during off duty hours (day versus night and weekend versus weekdays) and if any differences in treatment or outcome were apparent when comparing patients admitted in the year 2003 with patients admitted in the year 2006.
  
  
  METHODS
  We analyzed 2003-2006 data of a prospective registry and grouped patients by time, day, and year of admission. The evaluation was limited to patients that were diagnosed with ischaemic stroke and with OAT of <or= 3 h. Medical and sociodemographic items, use of thrombolytic treatment, complications during clinical course and place of discharge were obtained. Clinical state on admission and discharge was assessed using the modified Rankin scale. Comparison with chi-square test, t-test and logistic regression was performed.
  
  
  RESULTS
  Patient's characteristics, rate of thrombolysis, and outcome were independent from time or day of admission. Proportion of patients with good clinical state at discharge increased significantly from 2003 to 2006 together with a higher rate of rTPA treatment without increase of intracranial hemorrhage. Proportion of patients discharged in good clinical condition after rTPA treatment increased from 34% to 44%.
  
  
  CONCLUSIONS
  Stroke treatment in potential candidates for thrombolytic therapy revealed no impairment on weekend or at night already in 2003. During 4 years, it was possible to increase rate of rTPA treatment from 8.9% to 21.8% without increment of complications or death, confirming that rTPA is safe and can be implemented with full daily and weekly coverage.
authors.affiliation: Department of Neurology, Okumenisches Hainich Klinikum Mühlhausen, Thüringen, Germany. marek.jauss@neuro.med.uni-giessen.de
authors.forename: M
authors.initials: M
authors.lastname: Jauss
authors.forename: H J
authors.initials: HJ
authors.lastname: Schütz
authors.forename: C
authors.initials: C
authors.lastname: Tanislav
authors.forename: B
authors.initials: B
authors.lastname: Misselwitz
authors.forename: F
authors.initials: F
authors.lastname: Rosenow
mesh_terms: D000208:Acute Disease; D000368:Aged; D000369:Aged, 80 and over; D002545:Brain Ischemia / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D020300:Intracranial Hemorrhages / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology; D008297:Male; D010343:Patient Admission; D017440:Photoperiod; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000627:therapeutic use; D012042:Registries; D012720:Severity of Illness Index; D012959:Socioeconomic Factors; D020521:Stroke / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology*; D015912:Thrombolytic Therapy; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator